medigraphic.com
Academia Mexicana de Neurología, A.C.

2018, Número 1

<< Anterior Siguiente >>

Rev Mex Neuroci 2018; 19 (1)


Taupatía asociada a anticuerpos anti-IgLON5

García-Nuño DK, Ramírez VLHJ, Soto EJA, Zúñiga RC

Idioma: Español
Referencias bibliográficas: 24
Paginas: 94-103
Archivo PDF: 429.62 Kb.


RESUMEN

Los anticuerpos contra IgLON5 se han encontraron en sujetos con un cuadro caracterizado por alteraciones del sueño acompañadas de inestabilidad para la marcha y alteración de movimientos oculares, síntomas bulbares, movimientos anormales, disautonomía y deterioro cognitivo. Estos pacientes poseen alelos HLA DRB1*1001 y DQB1*0501 y hallazgos histopatológicos de neurodegeneración con acúmulo intracelular de proteína Tau hiperfosforilada sobre todo en hipotálamo y tallo cerebral, sin cambios inflamatorios. Aunque las enfermedades neurológicas asociadas a anticuerpos contra antígenos de superficie suelen responder bien a la inmunoterapia, en esta enfermedad muestran pobre respuesta y un pronóstico generalmente fatal, por lo que representa un cruce entre los mecanismos inmunológicos y de neurodegeneración.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: A case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13(6):575–86.

  2. Simabukuro MM, Sabater L, Adoni T, Cury RG, Haddad MS, Moreira CH, et al. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol NeuroInflammation. 2015;2(4):1–2.

  3. Huijbers MG, Querol LA, Niks EH, Plomp JJ, van der Maarel SM, Graus F, et al. The expanding field of IgG4-mediated neurological autoimmune disorders. Eur J Neurol. 2015;22(8):1151–61.

  4. Gelpi E, Höftberger R, Graus F, Ling H, Holton JL, Dawson T, et al. Neuropathological criteria of anti- IgLON5-related tauopathy. Acta Neuropathol. 2016;132(4):531–43.

  5. Sabater L, Planagumà J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation. 2016;13(1):226.

  6. Gaig C, Graus F, Compta Y, Högl B, Bataller L, Brüggemann N, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88(18):1736–43.

  7. Archelos JJ, Hartung HP. Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci. 2000;23(7):317–27.

  8. Gold M, Pul R, Bach JP, Stangel M, Dodel R. Pathogenic and physiological autoantibodies in the central nervous system. Immunol Rev. 2012;248(1):68–86.

  9. Honorat JA, Komorowski L, Josephs KA, Fechner K, St Louis EK, Hinson SR, et al. IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. Neurol - Neuroimmunol Neuroinflammation. 2017;4(5):1–8.

  10. Dale RC, Ramanathan S. Cell surface antibody-associated neurodegeneration: The case of anti- IgLON5 antibodies. Neurology. 2017;88(18):1688–90.

  11. Balint B, Bhatia KP. Stiff person syndrome and other immune-mediated movement disorders – new insights. Curr Opin Neurol. 2016;29(4):1.

  12. Hashimoto T, Maekawa S, Miyata S. IgLON cell adhesion molecules regulate synaptogenesis in hippocampal neurons. Cell Biochem Funct. 2008;27:496–8.

  13. Tan, R.P., Leshchyns’ka, I, Sytnyk, V. Glucosylphosphatidilinositol-Anchored Immunoglobulin Superfamily Cell Adhesion Molecules and Their Role in Neuronal Development and Synapse Regulation. Front Mol Neurosci. 2017;10:378.

  14. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Parsons TD, et al. Cellular and Synaptic Mechanisms of Anti-NMDAR Encephalitis. J Neurosci. 2010;30(17):5866–75.

  15. Cagnin A, Mariotto S, Fiorini M, Gaule M, Bonetto N, Tagliapietra M, et al. Microglial and Neuronal TDP-43 Pathology in Anti-IgLON5-Related Tauopathy. J Alzheimer’s Dis. 2017;59:1–8.

  16. Högl B, Heidbreder A, Santamaria J, Graus F, Poewe W. IgLON5 autoimmunity and abnormal behaviours during sleep. Lancet. 2015;385(9977):1590.

  17. Schröder JB, Melzer N, Ruck T, Heidbreder A, Kleffner I, Dittrich R, et al. Isolated dysphagia as initial sign of anti-IgLON5 syndrome. Neurol Neuroimmunol NeuroInflammation. 2017;4(1):1–6.

  18. Montojo MT, Piren V, Benkhadra F, Codreanu A, Wirt G, Kerschen P, et al. Mimicking Progressive Supranuclear Palsy And Causing Tako‐Tsubo Syndrome: A Case Report On IgLON5-Encephalopathy. Mov Disord. 2015;30(suppl 1):710.

  19. Brüggemann N, Wandinger KP, Gaig C, Sprenger A, Junghanns K, Helmchen C, et al. Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies. Mov Disord. 2016;31(5):762–4.

  20. Bahtz R, Teegen B, Borowski K, Probst C, Brücker I-M, Fechner K, et al. Autoantibodies against IgLON5: Two new cases. J Neuroimmunol. 2014;275(1–2):8.

  21. Salmon DP, Filoteo JV. Neuropsychology of cortical versus subcortical dementia syndromes. Semin Neurol. 2007;27(1):7–21.

  22. Haitao R, Yingmai Y, Yan H, Fei H, Xia L, Honglin H, et al. Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy. J Neuroimmunol. 2016;300:9–10.

  23. Lang K, Prüss H. Frequencies of neuronal autoantibodies in healthy controls. Neurol - Neuroimmunol Neuroinflammation. 2017;4(5):1–8.

  24. Zhang W, Niu N, Cui R. Serial 18 F-FDG PET/CT Findings in a Patient With IgLON5 Encephalopathy. Clin Nucl Med. 2016;41(10):787–8.




2020     |     www.medigraphic.com